

Emerging Therapies in Advanced Melanoma



This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of New York Medical College (NYMC) and the Continuing Education Alliance. NYMC is accredited by the ACCME to provide continuing medical education for physicians. NYMC designates this educational activity for a maximum of 2.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

Oncologists

Faculty

Michael B. Atkins, MD, *Chair*
Deputy Chief, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center
Director of Biologic Therapy and Cutaneous Oncology Programs
Director, Cancer Clinical Trials Office
Associate Director for Clinical Research, Beth Israel Deaconess Cancer Center
Leader, Kidney Cancer Program, Dana-Farber/Harvard Cancer Center
Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Keith T. Flaherty, MD
Assistant Professor of Medicine
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

Mario Sznol, MD
Associate Professor and Vice-Chief, Medical Oncology
Co-Director, Melanoma Program
Yale Cancer Center, New Haven, Connecticut

Michael K. K. Wong, MD, PhD, FRCPC
Medical Director, Clinical Drug Development and Biologic Therapy
Department of Medicine, Pharmacology and Immunology
Roswell Park Cancer Institute, Buffalo, New York

This activity is supported by an unrestricted educational grant from Pfizer Inc.

Learning objectives

After completion of this activity, participants should be better able to:

- Discuss mechanisms of action and the recent efficacy and toxicity data available on the promising therapies in development for melanoma;
- Identify available phase II or III clinical trials with these new therapies and refer appropriate patients for enrollment in studies;
- Develop an understanding of the issues surrounding the treatment of metastatic melanoma and put new data into clinical context.

Faculty disclosures

All faculty and planners participating in continuing medical education activities sponsored by NYMC are expected to disclose to the audience any significant support or substantial relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias and based upon all the available scientifically rigorous data from research that conform to accepted standards of experimental design, data collection, and analysis.

Unapproved/investigative (“off-label”) use of products is discussed in this activity.

Dr. Atkins: *grants/research support:* Bayer/Onyx, Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation, Schering-Plough

Dr. Flaherty: *honoraria/consultant:* AstraZeneca Pharmaceuticals, Schering-Plough

Dr. Sznol: *honoraria/consultant:* Bristol-Myers Squibb, Genzyme, Pfizer Inc

Dr. Wong: has no relevant financial relationship with any commercial interests to disclose

The Planning Committee for this activity included Kathy Johnston-Kavanagh and Margaret Astrologo of NYMC and Ruth Cohen and Mary Kay Barton, MD, of the Continuing Education Alliance. The members of the Planning Committee have no significant relationships to disclose.

How to receive credit

Oncologists wishing to receive 2.0 *AMA PRA Category 1 Credit(s)*TM must:

1. Read the supplement articles.
2. Relate the content material to the learning objectives.
3. Answer the self-assessment questions (pages 31–32), complete the evaluation form facing page 32, and return it as indicated to NYMC. A CME certificate will be mailed to you upon successful completion of the requirements.

The estimated time to complete this activity is 2 hours.

Release date: March 15, 2008

Expiration date: Credit will be awarded for required materials received no later than March 15, 2009.

Disclaimer

The opinions or views expressed in this CME activity do not necessarily reflect the opinions or recommendations of the Continuing Education Alliance, NYMC, or Pfizer Inc.